The five-year figure doesn't always determine which cancer types are most commonly being studied in late-phase trials.
Five-year disease prevalence is certainly a factor-but apparently not the only one-determining which cancer types are most commonly being studied in late-phase clinical trials. IMS Health's analysis of the distribution of Phase III trials reveals that, as would be expected, cancers with higher five-year disease prevalence are the subject of more late-phase trials. But there are exceptions (see Figure 1).
The first is lung cancer. It is the clear leader in terms of the volume of Phase III trials, yet has about the same five-year prevalence as cervical and stomach cancers, both of which are involved in dramatically fewer trials. This may be tied to the fact that the molecular targets in non-small cell lung cancer have been long-since identified and extensively studied. The second exception is ovarian cancer, which has one of the lowest five-year prevalence rates, but is being heavily studied in Phase III trials due to the fact that several genetic mutations can affect the outcome for ovarian cancer patients.
Thus, a low five-year disease prevalence does not always inhibit research investment, provided that the genetic target can be identified in patients. - IMS Health
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.